Navigation Links
Hilary Swank to Spearhead Cancer Hair-loss Campaign

Oscar-winning actress Hilary Swank will soon be seen in action spearheading a charity campaign that aims at supporting women who have lost their hair as a result of cancer treatment.

The Pantene Beautiful Lengths drive encourages people to grow their locks, get it cut, and donate it for making wigs for women who have lost their hair during cancer treatment.

Swank, who joins the campaign from 2008, will donate her own hair too.

"I have lost multiple family members to cancer and witnessed their struggle first hand, Contactmusic quoted her as saying.

"I've never heard of anything quite like Pantene Beautiful Lengths, and I'm proud to be asked to promote the goals of such a unique and heartfelt program," she added.


'"/>




Page: 1

Related medicine news :

1. Hilary Duff was obsessed With Her Weight
2. Nanotechnology Revolution To Be Spearheaded By European Union
3. WHO Spearheads a Global Initiative for Development of Malaria Vaccine by 2015
4. Two MSU Professors Spearhead International Water Project
5. Fibroids unlikely to Turn Cancerous
6. Virus Level could Predict Cervical Cancer Risk
7. Cancer Doctors Okays Controversial Prostate Therapy
8. Potential New Cancer Gene Identified
9. Consensus on "Combination Therapy" for Breast Cancer
10. Cancers of Colon & Rectum linked to Cigarette Smoking
11. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
Post Your Comments:
(Date:5/15/2008)...5 /PRNewswire-FirstCall/ -- Lung cancer patients,w...s may fare better as a,result, according to data f...linical trial. Data from the trial, which involved... injection), will be presented at the 44th Annual,...gy (ASCO) in Chicago,Ill., May 30 -- June 3, 2008...
(Date:5/15/2008)...h the goal of tailoring cancer treatment for each ...edical Center today presented a study suggesting a...assess treatment efficacy for patients with metast...and sometimes months to determine if a particular ...at long to observe any significant radiographic ch...
(Date:5/15/2008)...coxib, the anti-inflammatory medication also known... and reduces a specific proliferation measurement ...a study from The University of Texas M. D. Anderso...nificance of COX-2 inhibition toward preventing lu...ing the disease. , The study is the first large ...
(Date:5/15/2008)... 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharm...GTEC) ("Genesis" or,the "Company"), a U.S. pharmac...he People,s Republic of China, today announced its... 2008, the Company,s third quarter of its,fiscal y...r the quarter,with the U.S. Securities Exchange Co...
Breaking Medicine News(10 mins):Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12
...r Medco Health solutions Inc. claims that parents ...he drugs themselves. // The study examined the pre...ast year. The study also found that if one twin i...ly that the other would also take it than non-twin...
...cine that it says can ward off common allergies su...e by Cytos Biotechnology has been tested on humans...n the TB bug, reported the online edition of Daily...doubled in the past 20 years, with the condition a...
...ocacy group, Families USA, suggests that majority ... have at least one parent employed full-time//. An...be earning members. The group's executive directo...eve these are low-income people who don't work, wh...
...ple suffering a severe personality disorder are po...ealth Services are putting their best foot forward...959 Mental Health Act has indicated that chronical...stay in Mental Healthcare Hospitals, if their illn...
Other Medicine News:
(Date:5/15/2008)...tion Most Affected by Disease -, WAYNE, N.J. and ...--,Bayer HealthCare Pharmaceuticals, Inc. and Onyx...unced that Nexavar(R) (sorafenib) tablets,signific...R=0.68;,p-value=0.014) in patients in the Asia-Pac... (HCC), or primary liver cancer versus those,recei...
(Date:5/15/2008)...all/ -- Medivation, Inc.,(Nasdaq: MDVN ) today an...al,trial of its novel androgen receptor antagonist...on at the 44th American Society of Clinical Oncolo...itle: New Targeted Strategies for Patients with Pr... 2 at 11:30 a.m. Central Time Abstract title: "Ph...
(Date:5/15/2008)...eptable Tolerability Profile, with Low... LAKE, N.J., May 15 /- The investigat...389) demonstrated activity in a,heavily pretreated...static,breast cancer, according to results of a mu... suggests that eribulin mesylate has a manageable,...
(Date:5/15/2008)...stCall/ -- Schering-Plough,Corporation (NYSE: SGP...t of,chronic hepatitis C virus (HCV) infection, an...ies with PEGINTRON(TM) (peginterferon alfa-2b) and...as well as boceprevir, the,company,s investigation...at,the 39th annual Digestive Disease Week (DDW) me...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Breast cancer more aggressive among obese women 14374 1Breast cancer more aggressive among obese women 14374 2Physicists discover how fundamental particles lose track of quantum mechanical properties 3966 1Physicists discover how fundamental particles lose track of quantum mechanical properties 3966 2Physicists discover how fundamental particles lose track of quantum mechanical properties 3966 3MannKind to Present at the Cowen and Company Healthcare Conference 14372 1Dont Prescribe Antibiotics for Adult Sinus Woes 14369 1Dont Prescribe Antibiotics for Adult Sinus Woes 14369 2Dont Prescribe Antibiotics for Adult Sinus Woes 14369 3Dont Prescribe Antibiotics for Adult Sinus Woes 14369 4
...ration,Biopharmaceuticals today announced the pres...pment of new, proprietary forms of,recombinant Fac...ta,were highlighted in an oral presentation and a ...ational Society on Thrombosis and,Haemostasis (IST....D., Associate Professor, UNC School of,Medicine, ...
...B8F) announces today,that it has received very pos...e IIb/III clinical trial started in autumn 2006. B...e 5-aminolevulinic acid,(ALA) with the nanoemulsio...to placebo in the treatment of actinic keratosis. ...eliminates tumor tissue,through a combination of a...
Other Medicine Technology:Inspiration Biopharmaceuticals Presents Data From Hemophilia,Program at International Society On Thrombosis and Haemostasis,(ISTH) Annual Meeting 2Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis 2
Liquichek Unassayed Chemistry Control (Human) is a comprehensive, stable, liquid product designed to monitor general and special chemistry tests.
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies.
Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels.
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing.
Medicine Products: